BR112017027887A2 - partículas e suspensões radioterapêuticas - Google Patents

partículas e suspensões radioterapêuticas

Info

Publication number
BR112017027887A2
BR112017027887A2 BR112017027887A BR112017027887A BR112017027887A2 BR 112017027887 A2 BR112017027887 A2 BR 112017027887A2 BR 112017027887 A BR112017027887 A BR 112017027887A BR 112017027887 A BR112017027887 A BR 112017027887A BR 112017027887 A2 BR112017027887 A2 BR 112017027887A2
Authority
BR
Brazil
Prior art keywords
particles
suspensions
radionuclide
radiotherapeutic
radiotherapeutic particles
Prior art date
Application number
BR112017027887A
Other languages
English (en)
Inventor
Hartvig Larsen Roy
Westrøm Sara
Original Assignee
Oncoinvent As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoinvent As filed Critical Oncoinvent As
Publication of BR112017027887A2 publication Critical patent/BR112017027887A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F11/00—Compounds of calcium, strontium, or barium
    • C01F11/18—Carbonates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/44—Alpha, beta or gamma radiation related properties

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Geology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção se refere a uma partícula ou composição farmacêutica que compreende uma, mais partículas ou uma suspensão das partículas iguais ou diferentes compreendendo um composto degradável e um radionuclídeo emissor de partículas alfa e/ou um radionuclídeo gerando uma filha emissora de partículas alfa. as partículas são benéficas para uso no tratamento do câncer.
BR112017027887A 2015-07-03 2016-07-01 partículas e suspensões radioterapêuticas BR112017027887A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201514791313A 2015-07-03 2015-07-03
EP15175318.3A EP3111959B1 (en) 2015-07-03 2015-07-03 Radiotherapeutic particles and suspensions
US14/798,258 US9539346B1 (en) 2015-07-03 2015-07-13 Radiotherapeutic particles and suspensions
PCT/EP2016/065573 WO2017005648A1 (en) 2015-07-03 2016-07-01 Radiotherapeutic particles and suspensions

Publications (1)

Publication Number Publication Date
BR112017027887A2 true BR112017027887A2 (pt) 2018-11-06

Family

ID=53514058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027887A BR112017027887A2 (pt) 2015-07-03 2016-07-01 partículas e suspensões radioterapêuticas

Country Status (20)

Country Link
US (1) US9539346B1 (pt)
EP (1) EP3111959B1 (pt)
JP (2) JP6526256B2 (pt)
KR (1) KR102401023B1 (pt)
CN (2) CN111760038B (pt)
AU (1) AU2016289408B2 (pt)
BR (1) BR112017027887A2 (pt)
CA (1) CA2991080C (pt)
DK (1) DK3111959T3 (pt)
ES (1) ES2649985T3 (pt)
HU (1) HUE034806T2 (pt)
MX (1) MX371221B (pt)
NO (1) NO3111959T3 (pt)
NZ (1) NZ738119A (pt)
PL (1) PL3111959T3 (pt)
PT (1) PT3111959T (pt)
RS (1) RS56646B1 (pt)
RU (1) RU2770073C2 (pt)
SI (1) SI3111959T1 (pt)
WO (1) WO2017005648A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
NO3111959T3 (pt) * 2015-07-03 2018-02-10
DK3568205T3 (da) * 2017-01-12 2023-10-09 Radiomedix Inc Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater
EP3773896A4 (en) 2018-04-02 2022-01-12 Alpha TAU Medical Ltd. CONTROLLED RELEASE OF RADIONUCLIDES
EP3563875A1 (en) * 2018-05-04 2019-11-06 Ceské vysoké ucení technické v Praze Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment
US20230372554A1 (en) * 2020-09-15 2023-11-23 Oncoinvent As Size controlled radiolabelled particles
US20230264044A1 (en) * 2022-02-24 2023-08-24 Alpha Tau Medical Ltd. Convection-Enhanced Diffusing Alpha-Emitter Radiation Therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191507385A (en) * 1914-05-18 1915-10-28 Siegmund Saubermann Process for Rendering Liquids Radio-active.
US4970062A (en) 1989-05-30 1990-11-13 The United States Of America As Represented By The United States Department Of Energy Colloid labelled with radionuclide and method
CA2326977A1 (en) * 1998-04-03 1999-10-14 Dupont Pharmaceuticals Company Inorganic material for radioactive drug delivery
JP3615681B2 (ja) * 1999-03-25 2005-02-02 幸男 古城 排気ガス軽減アルミニウムシートの製造方法
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
GB0403856D0 (en) * 2004-02-20 2004-03-24 Algeta As Composition
CA2555435C (en) 2004-02-20 2011-07-12 Algeta As Alpha-emitting hydroxyapatite particles
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
JP3123645U (ja) * 2006-02-21 2006-07-27 株式会社シガドライセンター マットレス
WO2009111437A2 (en) * 2008-03-03 2009-09-11 Massachusetts Institute Of Technology Monodispersed organic monolayer coated calcium-containing nanoparticles
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
CN203315383U (zh) * 2012-09-25 2013-12-04 唐伟钊 一种带放疗功能的纳米抗癌药物
NO3111959T3 (pt) * 2015-07-03 2018-02-10

Also Published As

Publication number Publication date
ES2649985T3 (es) 2018-01-16
CA2991080C (en) 2023-10-10
NO3111959T3 (pt) 2018-02-10
PL3111959T3 (pl) 2018-03-30
AU2016289408B2 (en) 2020-10-29
CN111760038B (zh) 2023-03-17
RU2017145907A (ru) 2019-08-05
DK3111959T3 (en) 2018-01-02
KR102401023B1 (ko) 2022-05-20
US20170000911A1 (en) 2017-01-05
CA2991080A1 (en) 2017-01-12
PT3111959T (pt) 2017-12-14
MX371221B (es) 2020-01-08
RU2770073C2 (ru) 2022-04-14
RU2017145907A3 (pt) 2019-12-27
CN107848827B (zh) 2020-08-04
KR20180024015A (ko) 2018-03-07
JP7084350B2 (ja) 2022-06-14
JP6526256B2 (ja) 2019-06-05
JP2019142952A (ja) 2019-08-29
AU2016289408A1 (en) 2018-01-04
CN107848827A (zh) 2018-03-27
SI3111959T1 (en) 2018-04-30
JP2018519338A (ja) 2018-07-19
NZ738119A (en) 2022-02-25
EP3111959B1 (en) 2017-09-13
WO2017005648A1 (en) 2017-01-12
US9539346B1 (en) 2017-01-10
RS56646B1 (sr) 2018-03-30
CN111760038A (zh) 2020-10-13
EP3111959A1 (en) 2017-01-04
HUE034806T2 (en) 2018-02-28
MX2017016938A (es) 2018-05-14

Similar Documents

Publication Publication Date Title
BR112017027887A2 (pt) partículas e suspensões radioterapêuticas
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
BR112018012145A2 (pt) partículas de entrega de pró-sabor
ZA201906832B (en) Novel psma-binding agents and uses thereof
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2019003938A (es) Compuestos espirociclicos.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
BR112016023517A2 (pt) produção de células t projetadas por transpóson sleeping beauty acoplado com seleção de metotrexato
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
EA033300B1 (ru) Диоксолановые аналоги уридина для лечения рака
BR112017000800A8 (pt) Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
MX2017012553A (es) Compuestos espirociclicos.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
BR112018006870A2 (pt) nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
MX2017014436A (es) Compuestos biciclicos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]